S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

NCT00238212 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Extrahepatic Bile Duct
Adenocarcinoma of the Gallbladder
Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Squamous Cell Carcinoma of the Gallbladder
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer

Interventions

DRUG: sorafenib tosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)